UNITED THERAPEUTICS (UTHR) CFO pre-planned option exercise and 10,000-share sale
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sale transaction in company stock. He exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at weighted average prices generally between about $568 and $579 per share. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, he directly holds 18,876 shares of Common Stock.
Positive
- None.
Negative
- None.
Insights
CFO exercised 10,000 options and sold 10,000 shares under a pre-planned Rule 10b5-1 plan.
CFO and Treasurer James Edgemond exercised stock options covering 10,000 shares of UNITED THERAPEUTICS Common Stock at an exercise price of $135.42 per share. On the same date, he executed open-market sales totaling 10,000 shares across multiple trades, with reported weighted average prices around $572–$579 per share.
The filing identifies these as open-market sales (code S) and an option exercise (code M), a classic exercise-and-sell pattern that converts an option position into cash. A key detail is that the activity occurred pursuant to a Rule 10b5-1 trading plan entered on October 31, 2025, indicating the trades were pre-scheduled rather than discretionary.
After the transactions, Edgemond directly owns 18,876 shares of Common Stock, so he retains a meaningful equity stake. The derivativeSummary is empty, showing no remaining options from this particular grant. Overall, this appears as routine, pre-planned liquidity rather than an abrupt change in exposure, and on its own does not clearly alter the company’s investment profile.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares ($5,744,746)
Net Sell
12 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.74M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 80 | $568.7394 | $45K |
| Sale | Common Stock | 80 | $570.5188 | $46K |
| Sale | Common Stock | 603 | $571.5252 | $345K |
| Sale | Common Stock | 970 | $572.7823 | $556K |
| Sale | Common Stock | 2,456 | $574.036 | $1.41M |
| Sale | Common Stock | 3,419 | $574.7609 | $1.97M |
| Sale | Common Stock | 1,712 | $575.7814 | $986K |
| Sale | Common Stock | 293 | $576.7505 | $169K |
| Sale | Common Stock | 307 | $577.9287 | $177K |
| Sale | Common Stock | 80 | $578.585 | $46K |
Holdings After Transaction:
Stock Option — 2,500 shares (Direct, null);
Common Stock — 28,876 shares (Direct, null)
Footnotes (1)
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $577.41 to $578.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $578.49 to $578.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $568.685 to $569.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $570.01 to $570.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $571.17 to $572.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $572.21 to $573.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $573.33 to $574.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $574.33 to $575.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $575.33 to $576.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $576.41 to $577.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 10,000 shares
Shares exercised: 10,000 shares
Exercise price: $135.42/share
+4 more
7 metrics
Shares sold
10,000 shares
Total Common Stock sold in open-market trades on 2026-05-14
Shares exercised
10,000 shares
Common Stock acquired via stock option exercise on 2026-05-14
Exercise price
$135.42/share
Strike price of stock options exercised into 10,000 shares
Representative sale price
$578.5850/share
Weighted average price for one reported open-market sale tranche
Another sale price
$574.7609/share
Weighted average price for another sale tranche of 3,419 shares
Shares held after
18,876 shares
Direct Common Stock ownership following all reported transactions
Remaining options from grant
2,500 options
Stock options remaining after exercising 10,000 of 12,500 total
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What did UNITED THERAPEUTICS (UTHR) CFO James Edgemond report in this Form 4?
He reported exercising stock options for 10,000 UNITED THERAPEUTICS shares and selling 10,000 shares in open-market trades. The trades converted an existing option position into common stock and then into cash, while leaving him with a continuing direct shareholding.
What stock options did the UNITED THERAPEUTICS (UTHR) CFO exercise in this filing?
He exercised stock options on 10,000 underlying shares of UNITED THERAPEUTICS Common Stock. The options carried an exercise price of $135.42 per share and had an original expiration date of March 15, 2027, with 2,500 option shares remaining after the exercise.
Does this UNITED THERAPEUTICS (UTHR) Form 4 indicate a change in derivative positions?
It shows the exercise of 10,000 stock options into common shares, reducing that specific option position. The derivativeSummary section is empty after the exercise, meaning no remaining derivative positions from this particular option grant appear in the filing’s derivatives table.